ZURICH:Nestle (NESN.S) said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics (AIMT.O) it does not already own, adding a potential blockbuster to its health science portfolio.
The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million Nestle had already invested in Aimmune, Nestle said in a statement.
Source: Reuters, Reporting by Silke Koltrowitz, editing by John Miller
